MarketCapExport financials
Jazz Pharmaceuticals plc (JAZZ)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Jazz Pharmaceuticals plc Balance Sheet 2025-2008 | JAZZ
Brief overview of Jazz Pharmaceuticals plc's financial position
The balance sheet is assessed across five available annual reports spanning 2015 to 2019.
Assets reached $5.5 billion, compared with $3.3 billion at the beginning. Growth of +66.2% and CAGR near 13.5% show active expansion.
Assets outpaced liabilities, +66.2% versus +40%. Dependence on external funding declined.
Internal capital represents 56.2% of the balance sheet, previously 48%. This is a strong capital position.
Each unit of equity supports about 0.41x of net debt. Dependence on debt remains comfortable.
Cash equals 11.5% of the balance sheet, compared with 29.7% five periods ago. This is the readily available cushion.
By the end of the period, accumulated earnings were $1.1 billion; the change from the start was +252.3%.
Overall picture
Jazz Pharmaceuticals plc's balance sheet looks resilient: assets are supported by substantial equity, while debt does not overwhelm financial flexibility.
Annual Balance Sheet Jazz Pharmaceuticals plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
2.95 B | 3.68 B | 3.62 B | 4.83 B | 5.44 B | 805 M | 1.27 B | 1.38 B | 1.2 B | 1.66 B | 200 M | 658 M | -86.5 M | 69.6 M | -82.1 M | - | - | - |
Long Term Debt |
4.33 B | 6.08 B | 5.11 B | 5.69 B | 6.02 B | 1.85 B | 1.57 B | 1.56 B | 1.54 B | 1.99 B | 1.15 B | 1.33 B | 544 M | 427 M | - | - | - | - |
Long Term Debt Current |
14.3 M | 14.3 M | 19 M | 15.6 M | 15.4 M | 14.5 M | 12.7 M | 33.4 M | 40.6 M | 36.1 M | 37.6 M | 9.43 M | 5.57 M | 29.7 M | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | 2.06 B | 2.1 B | 2.12 B | 2.67 B | 1.51 B | 1.75 B | 739 M | 654 M | 7.9 M | - | - | - |
Total Current Liabilities |
2.24 B | 1.04 B | 1.54 B | 933 M | 809 M | 654 M | 364 M | 345 M | 294 M | 257 M | 227 M | 217 M | 204 M | 192 M | 52.9 M | 59.9 M | - | - |
Total Liabilities |
- | - | - | - | - | - | 2.43 B | 2.45 B | 2.41 B | 2.92 B | 1.73 B | 1.97 B | 943 M | 845 M | 60.8 M | - | - | - |
Deferred Revenue |
- | - | - | 463 K | 2.09 M | 2.55 M | 4.72 M | 5.41 M | 8.62 M | 1.12 M | 1.37 M | 1.14 M | 1.14 M | 1.14 M | 1.14 M | 1.27 M | - | - |
Retained Earnings |
646 M | 1.13 B | 879 M | 734 M | 830 M | 1.16 B | 1.07 B | 842 M | 918 M | 529 M | 303 M | 35.2 M | 19 M | -60.8 M | -350 M | -475 M | - | - |
Total Assets |
11.7 B | 12 B | 11.4 B | 10.8 B | 12.3 B | 6.54 B | 5.54 B | 5.2 B | 5.12 B | 4.8 B | 3.33 B | 3.34 B | 2.24 B | 1.97 B | 254 M | 136 M | - | - |
Cash and Cash Equivalents |
1.39 B | 2.41 B | 1.51 B | 881 M | 591 M | 1.06 B | 637 M | 310 M | 386 M | 366 M | 989 M | 684 M | 637 M | 387 M | 82.1 M | 44.8 M | 15.6 M | 24.9 M |
Book Value |
11.7 B | 12 B | 11.4 B | 10.8 B | 12.3 B | 6.54 B | 3.11 B | 2.76 B | 2.71 B | 1.88 B | 1.6 B | 1.37 B | 1.3 B | 1.12 B | 193 M | 136 M | - | - |
Total Shareholders Equity |
4.32 B | 4.09 B | 3.74 B | 3.09 B | 3.97 B | 3.66 B | 3.11 B | 2.76 B | 2.71 B | 1.88 B | 1.6 B | 1.37 B | 1.3 B | 1.12 B | 193 M | 30.6 M | -72.8 M | -92.9 M |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Jazz Pharmaceuticals plc
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
3.34 B | 4.32 B | 4.33 B | 4.34 B | 5.34 B | 6.08 B | 5.1 B | 5.11 B | 5.11 B | 5.69 B | 5.69 B | 5.69 B | 5.7 B | - | 5.99 B | 6.02 B | 6.25 B | 6.49 B | 1.85 B | 1.85 B | 1.85 B | 1.85 B | 1.85 B | 1.57 B | 1.57 B | 1.57 B | 1.57 B | 1.56 B | 1.56 B | 1.56 B | 1.56 B | 1.54 B | 1.54 B | 1.54 B | 1.54 B | 1.99 B | 1.99 B | 1.99 B | 1.99 B | 1.15 B | 1.15 B | 1.15 B | 1.15 B | 1.33 B | 1.33 B | 1.33 B | 1.33 B | 544 M | 544 M | 544 M | 544 M | 427 M | 427 M | 427 M | 427 M | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | 4 K | 4 K | 4 K | 463 K | 871 K | - | 1.69 M | 2.09 M | 2.27 M | 2.44 M | 2.37 M | 2.55 M | 2.55 M | 2.55 M | 2.55 M | 4.72 M | 4.72 M | 4.72 M | 4.72 M | 5.41 M | 5.41 M | 6.46 M | 6.98 M | 8.62 M | 8.62 M | 8.58 M | 8.62 M | 1.12 M | 1.12 M | 1.12 M | 1.12 M | 1.37 M | 1.37 M | 1.37 M | 1.37 M | 1.14 M | 1.14 M | 1.14 M | 1.14 M | 1.14 M | 1.14 M | 1.14 M | 1.14 M | 1.14 M | 1.14 M | 1.14 M | 1.14 M | 1.14 M | 1.14 M | 1.14 M | 1.14 M |
Retained Earnings |
1.13 B | 939 M | 443 M | 191 M | 1.03 B | 936 M | 871 M | 864 M | 884 M | 812 M | 803 M | 734 M | 974 M | - | 959 M | 830 M | 866 M | 918 M | 1.28 B | 1.16 B | 1.16 B | 1.16 B | 1.16 B | 1.07 B | 1.07 B | 1.07 B | 1.07 B | 841 M | 841 M | 841 M | 841 M | 918 M | 918 M | 918 M | 918 M | 529 M | 529 M | 529 M | 529 M | 303 M | 303 M | 303 M | 303 M | 34.7 M | 34.7 M | 34.7 M | 34.7 M | 18.5 M | 18.5 M | 18.5 M | 18.5 M | -61.3 M | -61.3 M | -61.3 M | -61.3 M | -350 M | -350 M | -350 M | -350 M |
Total Assets |
11.1 B | 11.9 B | 11.4 B | 10.9 B | 11.5 B | 12.3 B | 11.4 B | 11.3 B | 11.2 B | 11.3 B | 11 B | 10.8 B | 10.4 B | - | 11.8 B | 12.3 B | 12.5 B | 13.2 B | 6.76 B | 6.54 B | 6.54 B | 6.54 B | 6.54 B | 5.54 B | 5.54 B | 5.54 B | 5.54 B | 5.2 B | 5.2 B | 5.2 B | 5.2 B | 5.12 B | 5.12 B | 5.12 B | 5.12 B | 4.8 B | 4.8 B | 4.8 B | 4.8 B | 3.33 B | 3.34 B | 3.34 B | 3.34 B | 3.34 B | 3.34 B | 3.34 B | 3.34 B | 2.24 B | 2.24 B | 2.24 B | 2.24 B | 1.97 B | 1.97 B | 1.97 B | 1.97 B | 254 M | 254 M | 254 M | 254 M |
Cash and Cash Equivalents |
1.62 B | 1.84 B | 1.33 B | 1.19 B | 1.86 B | 2.22 B | 1.36 B | 1.44 B | 1.34 B | 1.28 B | 1.17 B | 881 M | 839 M | 711 M | 491 M | 591 M | 672 M | 891 M | 2.1 B | 1.06 B | 1.06 B | 1.06 B | 1.06 B | 637 M | 637 M | 637 M | 637 M | 310 M | 310 M | 310 M | 310 M | 386 M | 386 M | 386 M | 386 M | 366 M | 366 M | 366 M | 366 M | 989 M | 989 M | 989 M | 989 M | 684 M | 684 M | 684 M | 684 M | 637 M | 637 M | 637 M | 637 M | 387 M | 387 M | 387 M | 387 M | 82.1 M | 82.1 M | 82.1 M | 82.1 M |
Book Value |
11.1 B | 11.9 B | 11.4 B | 10.9 B | 11.5 B | 12.3 B | 11.4 B | 11.3 B | 11.2 B | 11.3 B | 11 B | 10.8 B | 10.4 B | - | 11.8 B | 12.3 B | 12.5 B | 13.2 B | 6.76 B | 6.54 B | 6.54 B | 6.54 B | 6.54 B | 5.54 B | 5.54 B | 5.54 B | 5.54 B | 5.2 B | 5.2 B | 5.2 B | 5.2 B | 5.12 B | 5.12 B | 5.12 B | 5.12 B | 4.8 B | 4.8 B | 4.8 B | 4.8 B | 3.33 B | 3.34 B | 3.34 B | 3.34 B | 3.34 B | 3.34 B | 3.34 B | 3.34 B | 2.24 B | 2.24 B | 2.24 B | 2.24 B | 1.97 B | 1.97 B | 1.97 B | 1.97 B | 254 M | 254 M | 254 M | 254 M |
Total Shareholders Equity |
4.8 B | 4.53 B | 3.96 B | 3.71 B | 4.17 B | 4.17 B | 3.76 B | 3.7 B | 3.49 B | 3.53 B | 3.34 B | 3.09 B | 2.75 B | 3.2 B | 3.61 B | 3.97 B | 3.94 B | 4.13 B | 3.8 B | 3.66 B | 3.66 B | 3.66 B | 3.66 B | 3.11 B | 3.11 B | 3.11 B | 3.11 B | 2.76 B | 2.76 B | 2.76 B | 2.76 B | 2.71 B | 2.71 B | 2.71 B | 2.71 B | 1.88 B | 1.88 B | 1.88 B | 1.88 B | 1.71 B | 1.56 B | 1.45 B | 1.31 B | 1.37 B | 1.37 B | 1.37 B | 1.37 B | 1.3 B | 1.3 B | 1.3 B | 1.3 B | 1.12 B | 1.12 B | 1.12 B | 1.12 B | 193 M | 193 M | 193 M | 193 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Jazz Pharmaceuticals plc, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Canada
USA
Russia
Niderland
France
Israel
Australia
Danmark
